Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLS101 in healthy volunteers
NCT07050368Phase 1Completed
- Sponsor
- MycoMedica Life Sciences
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lorundrostat in Premenstrual Dysphoric Disorder (PMDD), obsessive compulsive disorder (OCD) and opioid use disorder (OUD), sponsored by MycoMedica Life Sciences. Primary endpoints: Functional magnetic resonance imaging and Treatment-emergent adverse events. Started Jul 2025; status: completed.
02
Drugs
lorundrostat
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)obsessive compulsive disorder (OCD)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07050368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050368.